Welcome to our dedicated page for Naturl Alt Intl news (Ticker: NAII), a resource for investors and traders seeking the latest updates and insights on Naturl Alt Intl stock.
The Natural Alternatives International, Inc. (NAII) news page on Stock Titan aggregates company announcements, earnings releases, and regulatory updates for investors following this nutritional supplements manufacturer. NAI describes itself as a formulator, manufacturer, and marketer of customized nutritional supplements, with operations that include private-label contract manufacturing and patent and trademark licensing related to proprietary ingredients such as CarnoSyn® beta-alanine and TriBsyn™.
News items commonly include quarterly and annual financial results, where NAI reports net sales, segment performance for private-label contract manufacturing and CarnoSyn® beta-alanine royalty, licensing and raw material sales, and commentary on factors affecting profitability such as factory capacity utilization, sales mix, and operating costs. These releases also provide information on cash balances, working capital, and borrowing capacity under the company’s credit facility.
Investors can also find corporate and commercial updates, such as new or amended manufacturing agreements and distribution partnerships. For example, NAI has announced a multi-year Manufacturing Agreement with The Juice Plus+ Company covering capsule and powder products sold in over 24 markets, and a U.S. distribution agreement for TriBsyn™ with B&D Nutritional Ingredients. Such news highlights NAI’s customer relationships and the commercial rollout of its proprietary ingredients.
Another category of news covers product and scientific developments. NAI and CarnoSyn® Brands have issued press releases about clinical research on TriBsyn™, including a published study demonstrating increased beta-alanine bioavailability and elimination of paresthesia, as well as participation in scientific conferences like the ESPEN Congress on Clinical Nutrition & Metabolism.
By reviewing this news feed, readers can track NAII earnings announcements, material agreements, scientific milestones, and other company communications in one place.
CarnoSyn® Brands and Natural Alternatives International (NAII) have announced a new distribution partnership with B&D Nutritional Ingredients, effective October 1st, 2024. Under the agreement, B&D will distribute NAI's new carnosine booster, TriBsyn™, to U.S.-based nutritional supplement, functional food, and beverage markets. TriBsyn™ is a patent-pending ingredient that increases beta-alanine bioavailability while eliminating paresthesia sensation. The product targets various consumer segments including older adults, vegetarians, and vegans seeking to boost their carnosine levels.
Natural Alternatives International (NAI) and CarnoSyn® Brands will showcase TriBsyn™, a patent-pending formula, at the 46th ESPEN Congress on Clinical Nutrition & Metabolism in Milan, Italy from September 7-10, 2024. TriBsyn™ utilizes proprietary technology to increase beta-alanine bioavailability and absorption while eliminating paresthesia associated with high doses of beta-alanine.
The team will be at stand #16 to discuss the latest clinical evidence of TriBsyn™, which offers opportunities for various consumer groups, including older adults and vegans. Aaron Starr, VP of CarnoSyn® Brands, highlighted the product's potential in addressing the growing demand for healthy aging and wellness solutions. The team will also attend the 20th European Geriatric Medicine Society Congress in Valencia, Spain on September 18-20.
Natural Alternatives International (NAI) has unveiled TriBsyn™, a revolutionary carnosine booster under its CarnoSyn® Brands portfolio. This groundbreaking product utilizes CarnoSyn® beta-alanine and patent-pending technology to increase beta-alanine bioavailability and absorption while eliminating paresthesia, a common side effect. TriBsyn™ improves beta-alanine absorption by more than four times compared to conventional forms, allowing for lower dosages and increased formulation flexibility.
The product aims to support general wellness, including cognitive performance, muscle function in older adults, and slowing age-related health decline. NAI plans to launch TriBsyn™ commercially at the 46th ESPEN Congress in Milan, Italy, in September. The company expects this innovation to strengthen its presence in dietary supplement categories and fortified and medical foods markets, particularly targeting the aging population and those with plant-based diets.
Natural Alternatives International (NAII) announced its fiscal 2024 Q3 results, revealing a net loss of $1.6 million, or ($0.27) per diluted share, on net sales of $25.1 million. This compares to a $2.4 million net loss in Q3 of the prior year. Q3 net sales fell by 23%, driven by a 26% decrease in private-label contract manufacturing sales. However, CarnoSyn® beta-alanine revenue rose 13% to $2.7 million. For the nine months ending March 31, 2024, NAII reported a net loss of $5.3 million on net sales of $84.3 million, a 29% decrease year-over-year. Cash reserves stood at $12.4 million, with zero outstanding on their credit facility. The company expects to report a net loss for Q4 and fiscal 2024 due to ongoing market adjustments but forecasts future sales growth and a return to profitability with the reopening of their Carlsbad facility in May 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.